APRIOMED acquired by HALMA

Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio. The investment thesis centers on funding the global scale-up and commercial acceleration of an established, market-leading medical device platform. OrganOx leverages a proprietary technology, normothermic machine perfusion, which has already supported over 2,500 liver transplants worldwide

The acquisition of Biocorp by Novo Nordisk, achieved through the purchase of Bio Jag's 45.3% stake and a subsequent mandatory public tender offer, marks a significant shift in strategy, transitioning from a collaborative research and development model to a proprietary technology platform. Having previously mitigated risks associated with the Mallya technology through regulatory approvals and commercial validation, including agreements with prominent industry players such as Sanofi and Roche Diabetes Care, Biocorp's management had laid the groundwork for this transaction

Strengthening its strategic focus on natural specialty feed ingredients, Belgium-based Innovad, backed by its financial sponsor IK Partners through the IK IX Fund, has completed the acquisition of 100% of the share capital of Swiss company Herbonis along with its affiliates, including UK-based Wyreside. This targeted build-up transaction aligns with Innovad's investment thesis to expand into primary botanical ingredients and establish a global center of excellence in phytogenics and animal biomonitoring

Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer. The operation is financially underpinned by a bridge loan facility secured by the acquirer's parent company through J.P. Morgan, which is expected to be ultimately refinanced via long-term financial instruments potentially incorporating an equity component

Ardian has acquired a stake in Théradial, a specialized player in the French dialysis sector, with a consolidated presence in medical product distribution, pharmaceuticals, and healthcare software. This transaction is part of a strategic partnership with UI Investissement, which had previously invested in the company in 2017. Founded in 1998, Théradial employs around 90 staff in France and Italy, generating approximately 50 million euros in revenue, primarily from public healthcare establishments, private clinics, and home care service providers

Stanley Capital Partners acquired a majority stake in Laboratoire X.O following the liquidation of its former owner, Novalpina Capital. The deal resolved a year-long legal dispute between management and transitional managers (BRG). This new phase focuses on a strategic merger with Noden Pharma (another SCP portfolio company), providing X.O with a commercial platform in Ireland and the United States. The goal remains to triple revenue within 3-4 years through aggressive portfolio acquisitions.

Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions. The consortium is acquiring the majority stake from Ardian, following a successful five-year partnership.

Catalent has executed a definitive binding agreement to acquire Metrics Contract Services, a specialized CDMO subsidiary, from Australia-based Mayne Pharma Group. Concurrently with the main transaction, the parties established a five-year commercial supply agreement alongside a transition service agreement (TSA), ensuring a seamless operational integration and absolute supply continuity for the divesting parent’s retained product portfolio. This transaction represents a highly value-accretive platform investment purposefully designed to expand integrated global oral solid formulation capabilities

TPG Capital has signed a binding agreement to acquire a majority stake in DOC Generici from ICG and Mérieux Equity Partners. The strategic rationale for the transaction is driven by the continued expansion of the Italian generic drug market and DOC Generici's position as a reference brand for patients and healthcare providers. TPG intends to partner with the existing management team to accelerate the company’s leadership through significant investment in organic growth and external consolidation

Healthcare-focused investment firm Mérieux Equity Partners has completed the strategic merger of two of its existing portfolio companies, Addmedica and Laboratoires CTRS, creating a new consolidated entity named Theravia Pharma. As part of this corporate combination, the sponsor—which already held existing stakes in both businesses—elected to significantly increase its overall equity position. Mérieux EP rolled over its historical shares and convertible bonds while simultaneously acquiring additional equity, notably buying out the exiting founders of Addmedica